UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome

Alimentary pharmacology & therapeutics, 2007-08, Vol.26 (4), p.535-544

2007

Volltextzugriff (PDF)

Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery

Gut, 2010-05, Vol.59 (5), p.605-611

2010

Volltextzugriff (PDF)

Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada

Current oncology (Toronto), 2018-08, Vol.25 (4), p.e354-355

2018

Volltextzugriff (PDF)

Preferences of Canadian patients and physicians for adjuvant treatments for melanoma

Current oncology (Toronto), 2019-12, Vol.26 (6), p.e755-765

2019

Volltextzugriff (PDF)

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

Alimentary pharmacology & therapeutics, 2004-12, Vol.20 (11‐12), p.1317-1322

2004

Volltextzugriff (PDF)

Burden of illness for metastatic melanoma in Canada, 2011-2013

Current oncology (Toronto), 2016-12, Vol.23 (6), p.e563-570

2016

Volltextzugriff (PDF)

Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada

Current oncology (Toronto), 2018-02, Vol.25 (1), p.32-40

2018

Volltextzugriff (PDF)

Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

Value in health, 2014-05, Vol.17 (3), p.A83-A83

2014

Volltextzugriff (PDF)

PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE

Value in health, 2019-11, Vol.22, p.S453-S453

2019

Volltextzugriff (PDF)

Clustering and stability of functional lower gastrointestinal symptom after enteric infection

Neurogastroenterology and motility, 2012-06, Vol.24 (6), p.546-e252

2012

Volltextzugriff (PDF)

PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

Value in health, 2020-05, Vol.23, p.S39-S39

2020

Volltextzugriff (PDF)

PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

Value in health, 2020-05, Vol.23, p.S45-S45

2020

Volltextzugriff (PDF)

PFS/TTP as a potential surrogate for OS in HR+, HER2– MBC

Annals of oncology, 2017-09, Vol.28, p.v84-v85

2017

Volltextzugriff (PDF)

Is PFS a more relevant endpoint than OS in 1L HR+, HER2– MBC? A systematic literature review

Annals of oncology, 2017-09, Vol.28, p.v84-v84

2017

Volltextzugriff (PDF)

Shifts from Old to New Social and Ecological Environments in the Lesotho Highlands Water Scheme; Relocating Residents of the Mohale Dam Area

Journal of southern African studies, 2000-12, Vol.26 (4), p.633-654

Thabane, Motlatsi

2000

Volltextzugriff (PDF)

Cost-Effectiveness of Everolimus for Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal (GI) or Lung Origin -A Canadian Societal Health Care System Perspective

Value in health, 2016-11, Vol.19 (7), p.A734-A734

2016

Volltextzugriff (PDF)

PCN144 - Cost-Effectiveness of Everolimus for Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal (GI) or Lung Origin -A Canadian Societal Health Care System Perspective

Value in health, 2016-11, Vol.19 (7), p.A734-A734

2016

Volltextzugriff (PDF)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer

Breast cancer targets and therapy, 2018-01, Vol.10, p.69-78

2018

Volltextzugriff (PDF)

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem

International journal of clinical pharmacology and therapeutics, 2007-03, Vol.45 (3), p.188; author reply 189

2007

Volltextzugriff (PDF)

PCN90 - Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

Value in health, 2014-05, Vol.17 (3), p.A83-A83

2014

Volltextzugriff (PDF)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?

Cancer management and research, 2018-01, Vol.10, p.1015-1025

2018

Volltextzugriff (PDF)

Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Ontario health technology assessment series, 2012, Vol.12 (4), p.1-50

Thabane, M

2012

Volltextzugriff (PDF)

Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate

Digestive diseases and sciences, 2006-05, Vol.51 (5), p.864-868

2006

Volltextzugriff (PDF)

Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model

Ontario health technology assessment series, 2012, Vol.12 (12), p.1-61

2012

Volltextzugriff (PDF)

Liphokojoe of Kao: A Study of a Diamond Digger Rebel Group in the Lesotho Highlands

Journal of southern African studies, 2000-03, Vol.26 (1), p.105-121

Thabane, Motlatsi

2000

Volltextzugriff (PDF)

1 – 25 von 615

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(602)
Mit Volltextzugriff
(528)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Bmj Open
(31)
Trials
(19)
Current Controlled Trials In Cardiovascular Medicine
(17)
Pilot And Feasibility Studies
(15)
Journal Of Clinical Epidemiology
(14)
Value In Health
(14)
Gastroenterology
(12)
Plos One
(12)
Systematic Reviews
(12)
Pediatric Critical Care Medicine
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome

Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery

Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada

Preferences of Canadian patients and physicians for adjuvant treatments for melanoma

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

Burden of illness for metastatic melanoma in Canada, 2011-2013

Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada

Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE

Clustering and stability of functional lower gastrointestinal symptom after enteric infection

PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE

PFS/TTP as a potential surrogate for OS in HR+, HER2– MBC

Is PFS a more relevant endpoint than OS in 1L HR+, HER2– MBC? A systematic literature review

Shifts from Old to New Social and Ecological Environments in the Lesotho Highlands Water Scheme; Relocating Residents of the Mohale Dam Area

Cost-Effectiveness of Everolimus for Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal (GI) or Lung Origin -A Canadian Societal Health Care System Perspective

PCN144 - Cost-Effectiveness of Everolimus for Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal (GI) or Lung Origin -A Canadian Societal Health Care System Perspective

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem

PCN90 - Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?

Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis

Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate

Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model

Liphokojoe of Kao: A Study of a Diamond Digger Rebel Group in the Lesotho Highlands

Suchergebnisse filtern